High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment

Journal of Clinical Lipidology

Volumn 9, Issue 1, 2015, Pages 26-34

  Xu, Rui Xia ^a   Li, Sha ^a   Li, Xiao Lin ^a   Zhang, Yan ^a   Guo, Yuan Lin ^a   Zhu, Cheng Gang ^a   Wu, Na Qiong ^a   Qing, Ping ^a   Sun, Jing ^a   Dong, Qian ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary artery disease; Gensini score; High density lipoprotein subfraction; Risk factor

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UREA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ANGIOCARDIOGRAPHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; GENSINI SCORE; HIGH DENSITY LIPOPROTEIN SUBFRACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; THORAX PAIN; UREA NITROGEN BLOOD LEVEL; AGED; BLOOD; CORONARY ANGIOGRAPHY; MIDDLE AGED; ODDS RATIO; PATHOLOGY; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AGED; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; SEVERITY OF ILLNESS INDEX;

EID: 84927640747     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.11.003     Document Type: Article

References (34)

1. Acharjee S, Boden WE, Hartigan PM, et al. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol. 2013;62:1826-1833.
2. Lyons JG, O'Dea K, Walker KZ. Evidence for low high-density lipoprotein cholesterol levels in Australian indigenous peoples: a systematic review. BMC Public Health. 2014;14:545.
3. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on H-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20:1253-1268.
4. Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124:555-562.
5. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol. 2012;59:2058-2064.
6. Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-1291.
7. Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M, Montalto G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab. 2014;28:453-461.
8. Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov. 2014;13:445-464.
9. Superko HR, Pendyala L, Williams PT, Momary KM, King SB 3rd, Garrett BC. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol. 2012;6:496-523.
10. Rosenson RS, Brewer HB Jr., Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57:392-410.
11. Christogiannis LG, Kostapanos MS, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens. 2013;27:44-50.
12. Xu RX, Guo YL, Li XL, Li S, Li JJ. Impact of short-term low-dose atorvastatin on LDL and HDL subfraction phenotype. Clin Exp Pharmacol Physiol. 2014;41:475-481.
13. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
14. Sinning C, Lillpopp L, Appelbaum S, et al. Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol. 2013;102:495-503.
15. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370-378.
16. Kypreos KE, Gkizas S, Rallidis LS, Karagiannides I. HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochem Pharmacol. 2013;85:1575-1578.
17. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation. 1991;84:129-139.
18. Lorincz H, Katko M, Harangi M, et al. Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects. Clin Endocrinol (Oxf). 2014;81:370-377.
19. Goliasch G, Oravec S, Blessberger H, et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (
20. Williams PT. Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort. J Lipid Res. 2012;53:266-272.
21. Fendler W, Rizzo M, Borowiec M, et al. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol. 2014;51:625-632.
22. Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids. 2013;48:547-555.
23. Tian L, Long S, Li C, et al. High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes. Lipids Health Dis. 2012;11:54.
24. Moon JY, Kwon HM, Kwon SW, et al. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology. 2007;108:282-289.
25. Zhou C, Cao J, Shang L, et al. Reduced paraoxonase 1 activity as amarker for severe coronary artery disease. Dis Markers. 2013;35:97-103.
26. Platt DE, Ghassibe-Sabbagh M, Youhanna S, et al. Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography. J Thromb Thrombolysis. 2014 [Epub ahead of print].
27. Mitsutake R, Miura S, Zhang B, Saku K. HDL-associated factors provide additional prognostic information for coronary artery disease as determined by multi-detector row computed tomography. Int J Cardiol. 2010;143:72-78.
28. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
29. Zhao XQ, Kosinski AS, Barnhart HX, Superko HR, King SB 3rd. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. Med Sci Monit. 2003;9:CR48-54.
30. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999;99:1959-1964.
31. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
32. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol. 1998;18:1723-1729.
33. Williams PT, Superko HR, Haskell WL, et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol. 2003;23:314-321.
34. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 1990;119:1262-1267.